ARCHIVES

1. Centers for Disease Control and Prevention [CDC][2006] Fatalities and injuries from falls among older adults-United States, 1993-
2003 and 2001-2005 MMWR Morb Mortal Weekly REP 55[45]:1221-1224
2. A. Clowes, B. L. Riggs, and S. Khosla, "The role of the immune system in the pathophysiology of osteoporosis,"Immunological Reviews,
vol. 208, pp. 207-227,2005.
3. L. Ginaldi, M. C. Di Benedetto, and M. De Martinis, "Osteoporosis, inflammation and ageing," Immunity and Ageing, vol. 2, article 14,
2005.
4. J. R. Arron and Y. Choi, "Bone versus immune system," Nature, vol. 408, no. 6812, pp. 535-536, 2000.
5. S. Kotake, N. Udagawa, M. Hakoda et al., "Activated human T cells directly induce osteoclastogenesis from human monocytes:
6. possible role of T cells in bone destruction in reumatoid arthritis patients," Arthritis & Rheumatism, vol. 44, pp. 1003-1012, 2001.
7. I. Roato, M. Grano, G. Brunetti et al.,
8. "Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement," FASEB Journal, vol. 19, no. 2, pp. 228-230, 2005.
9. I. Roato, G. Brunetti, E. Gorassini et al., "IL-7 up-regulates TNF-a-dependent
10. osteoclastogenesis in patients affected by solid tumor," PLoS ONE, vol. 1, no. 1, article e124, 2006.
11. G. Brunetti, S. Colucci, P. Pignataro et al., "T cells support osteoclastogenesis in an in vitro model derived from human periodontitis
patients," Journal of Periodontology, vol. 76, no. 10, pp. 1675-1680, 2005.
12. S. Colucci, G. Brunetti, F. P. Cantatore et al.,
13. "Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFa, and IL-7 in an in vitro model derived
from human psoriatic arthritis," Journal of Pathology, vol. 212, no. 1, pp. 47-55, 2007
14. M. F. Faienza, G. Brunetti, S. Colucci et al. "Osteoclastogenesis in children with 21- hydroxylase deficiency on long-term
glucocorticoid therapy: the role of receptor activator of
15. nuclear factor-B ligand/osteoprotegerin imbalance," Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2269-2276,
2009.
16. G. Brunetti, M. F. Faienza, L. Picente et al.,
17. "High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment,"
American
18. Journal of Physiology, vol. 304, pp. 546-554,2013.
19. A. Ventura, G. Brunetti, S. Colucci et al.,
20. "Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency," BioMed Research International, vol. 2013,
21. Article ID 250462, 8 pages, 2013.
22. View at: Publisher Site | Google Scholar
23. [13.is JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9(8): 1137-
1141.
24. urge R, Dawson Hughes B, Solomon DH, Wong JB, King A, et al. (2007)
25. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3): 465-475.
26. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Baccaro LF, Conde DM, Costa-Paiva L,
Pinto-Neto AM. Clin Interv Aging. 2015;10:583–591.
27. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel. JAMA. 2001;285:785–795.
28. Secondary causes of osteoporosis. Fitzpatrick LA. Mayo Clin Proc. 2002;77:453–468.
29. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF.
Nat Med. 1996;2:1132–1136.
30. The bone remodelling cycle. Kenkre JS, Bassett J. Ann Clin Biochem. 2018;55:308–327.
31. Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Delaisse JM, Andersen TL, Kristensen HB, Jensen PR,
Andreasen CM, Søe K. Bone. 2020;141:115628.
32. The bone remodelling cycle. Kenkre JS, Bassett J. Ann Clin Biochem. 2018;55:308–327.
33. Prevention and treatment of postmenopausal osteoporosis. Tella SH, Gallagher JC. J Steroid Biochem Mol Biol. 2014;142:155–170.
34. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Parfitt AM. Bone.
2002;30:5–7.
35. Targeted and nontargeted remodeling. Burr DB. Bone. 2002;30:2–4. [PubMed] [Google Scholar]
36. The osteocyte: key player in regulating bone turnover. Goldring SR. RMD Open. 2015;1:0.
37. Osteocyte regulation of bone mineral: a little give and take. Atkins GJ, Findlay DM. Osteoporos Int. 2012;23:2067–2079.
38. Increased intracortical remodeling following fatigue damage. Mori S, Burr DB. Bone.
39. Osteopetrosis. Tolar J, Teitelbaum SL, Orchard PJ. N Engl J Med. 2004;351:2839–2849.
40. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Silver IA, Murrills RJ,
Etherington DJ. Exp Cell Res. 1988;175:266–276.
41. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Delaissé JM, Andersen TL, Engsig
MT, Henriksen K, Troen T, Blavier L. Microsc Res Tech. 2003;61:504–513.
42. Regulation of apoptosis in osteoclasts and osteoblastic cells. Xing L, Boyce BF. Biochem Biophys Res Commun. 2005;328:709–720.
43. Coupling the activities of bone formation and resorption: a multitude of signals within the basic
44. multicellular unit. Sims NA, Martin TJ. Bonekey Rep. 2014;3:481. [PMC free article]
45. Deposition of cement at reversal lines in rat femoral bone. Zhou H, Chernecky R, Davies JE. J Bone Miner Res. 1994;9:367–374.
46. The amazing osteocyte. Bonewald LF. J Bone Miner Res. 2011;26:229–238. [PMC free article] 35.International Osteoporosis
Foundation. Bone Turnover Markers Educational Course
47. Manolagas SC et al. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9(12):699-712.
48. . M. Brandão, G. P. Machado, and A. Acurcio Fde, “Pharmacoeconomic analysis of strategies to treat postmenopausal osteoporosis:
a systematic review,” Revista Brasileira de Reumatologia, vol. 52, pp. 924– 937, 2012.
49. C. MacLean, S. Newberry, M. Maglione et al., “Systematic review: comparative effectiveness of treatments to prevent fractures in men
and women with low bone density or osteoporosis,” Annals of Internal Medicine, vol. 148, no. 3, pp. 197–213, 2008.
50. A. Papaioannou, S. Morin, A. M. Cheung et al., “2010 clinical practice guidelines for the diagnosis and management of osteoporosis in
Canada: summary,” Canadian Medical Association Journal, vol. 182, no. 17, pp. 1864–1873, 2010.
51. C. J. Rosen and J. P. Bilezikian, “Clinical review 123: hot topic—anabolic therapy for osteoporosis,” Journal of Clinical Endocrinology
and Metabolism, vol. 86, no. 3, pp. 957–964, 2001.
52. J. M. Belavic, “Denosumab, (Prolia): a new option in the treatment of osteoporosis,” Nurse Practitioner, vol. 36, pp. 11–12, 2011.
53. M. J. Favus, “Bisphosphonates for osteoporosis,” The New England Journal of Medicine, vol. 363, no. 21, pp. 2027–2035, 2010.
54. N. B. Watts and D. L. Diab, “Long-term use of bisphosphonates in osteoporosis,” Journal of Clinical Endocrinology and Metabolism,
vol. 95, no. 4, pp. 1555–1565, 2010.
55. P. D. Miller, “A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis,” Therapeutic Advances in
Musculoskeletal Disease, vol. 3, pp. 271–282, 2011.
56. M. D. Moen and S. J. Keam, “Denosumab: a review of its use in the treatment of postmenopausal osteoporosis,” Drugs and Aging, vol.
28, no. 1, pp. 63–82, 2011.
57. R. Baron, S. Ferrari, and R. G. G. Russell, “Denosumab and bisphosphonates: different mechanisms of action and effects,” Bone, vol48, no. 4, pp. 677–692, 2011.
58. Compston JE, Watts NB (2002) Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf) 56(5): 565-569.
59. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al.
60. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausalosteoporosis. N Engl J Med
349(13): 1207-1215.
61. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal
62. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, et al. Relationship between bone mineral density t-score and
nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res 2019;34:1033–40. ArticlePubMed
63. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, et al. Goal-directed treatment for osteoporosis: a
progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017;32:3–10.
ArticlePubMed
64. Lewiecki EM. Osteoporosis: treat-to-target. Curr Osteoporos Rep 2017;15:103–9. ArticlePubMed
65. Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, et al. Change in bone density and reduction in fracture risk: a meta-
regression of published trials. J Bone Miner Res 2019;34:632–42. ArticlePubMed
66. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal
women: an Endocrine Society guideline update. J Clin Endocrinol Metab 2020;105:dgaa048.
67. ArticlePubMed55. Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission
of osteoporosis therapy. Osteoporos Int 2019;30:1733–43. ArticlePubMed
68. Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission of osteoporosis
therapy. Osteoporos Int 2019;30:1733–43. ArticlePubMed
69. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone
turnover. J Clin Endocrinol Metab 2011;96:3367–73. ArticlePubMedPMC
70. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years
of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–
38.ArticlePubMed.